Advanced in WT1-Related Wilms Tumor Syndromes

Dr. Mark W. Jalkut

Urology
Associated Urologists of North Carolina
Associated Urologists Of North Carolina PA
3821 Ed Dr, 
Raleigh, NC 
Accepting New Patients
Offers Telehealth

Advanced in WT1-Related Wilms Tumor Syndromes
Associated Urologists of North Carolina
Associated Urologists Of North Carolina PA
3821 Ed Dr, 
Raleigh, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Mark Jalkut is an Urologist in Raleigh, North Carolina. Dr. Jalkut is rated as an Advanced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Muscle Invasive Bladder Cancer, Ureteroscopy, and Reconstructive Urology Surgery. Dr. Jalkut is currently accepting new patients.

His clinical research consists of co-authoring 7 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Urology
Licenses
Urology in NC
Hospital Affiliations
Johnston Health
Rex Hospital
Languages Spoken
English
Slovak
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Essence Healthcare
  • INSURANCE PLAN
  • MEDICARE MAPD
FirstCarolinaCare
  • HMO
  • MEDICARE MAPD
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
TeamCare
  • OTHER COMMERCIAL
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

ASSOCIATED UROLOGISTS OF NORTH CAROLINA PA
3821 Ed Dr, Raleigh, NC 27612
Call: 919-758-8677

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


10 Clinical Trials

QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer
QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 14, 2025
Intervention Type: Drug
Study Drugs: ALT-803, Bacillus Calumette-Guerin
Study Phase: Phase 2/Phase 3
A Prospective, Multicenter, Double Blind, Randomized, Clinical Study to Evaluate the Safety and Efficacy of the Optilume™ BPH Catheter System in Men With Symptomatic BPH
A Prospective, Multicenter, Double Blind, Randomized, Clinical Study to Evaluate the Safety and Efficacy of the Optilume™ BPH Catheter System in Men With Symptomatic BPH
Enrollment Status: Active_not_recruiting
Publish Date: April 09, 2025
Intervention Type: Device
Study Phase: Not Applicable
VERACITY - Randomized, Active-Controlled, Phase 3 Study of VERU-111 for the Treatment of Metastatic Castration-Resistant Prostate Cancer in Patients Who Have Failed Prior Treatment With at Least One Androgen Receptor Targeting Agent
VERACITY - Randomized, Active-Controlled, Phase 3 Study of VERU-111 for the Treatment of Metastatic Castration-Resistant Prostate Cancer in Patients Who Have Failed Prior Treatment With at Least One Androgen Receptor Targeting Agent
Enrollment Status: Terminated
Publish Date: February 05, 2024
Intervention Type: Drug
Study Drugs: VERU-111, Enzalutamide, Abiraterone, Darolutamide and Apalutamide
Study Phase: Phase 3
A Post-Market Evaluation of the Altis® Single Incision Sling System Versus Transobturator or Retropubic Mesh Sling in the Treatment of Female Stress Urinary Incontinence
A Post-Market Evaluation of the Altis® Single Incision Sling System Versus Transobturator or Retropubic Mesh Sling in the Treatment of Female Stress Urinary Incontinence
Enrollment Status: Completed
Publish Date: December 04, 2023
Intervention Type: Device
A Phase III, Randomized, Multicenter, Parallel-Group, Double-Blind, Double-Dummy Study in Adolescent and Adult Female Participants Comparing the Efficacy and Safety of Gepotidacin to Nitrofurantoin in the Treatment of Uncomplicated Urinary Tract Infection (Acute Cystitis)
A Phase III, Randomized, Multicenter, Parallel-Group, Double-Blind, Double-Dummy Study in Adolescent and Adult Female Participants Comparing the Efficacy and Safety of Gepotidacin to Nitrofurantoin in the Treatment of Uncomplicated Urinary Tract Infection (Acute Cystitis)
Enrollment Status: Completed
Publish Date: July 18, 2023
Intervention Type: Drug
Study Drugs: Gepotidacin, Nitrofurantoin
Study Phase: Phase 3
Open-Label, Proof-of-Concept and Dose Finding Phase 1b/2 Study of VERU-100 in Men With Advanced Prostate Cancer
Open-Label, Proof-of-Concept and Dose Finding Phase 1b/2 Study of VERU-100 in Men With Advanced Prostate Cancer
Enrollment Status: Terminated
Publish Date: May 19, 2023
Intervention Type: Drug
Study Drug: VERU-100
Study Phase: Phase 1/Phase 2
Phase 1-2a Safety, Tolerability, and Pharmacodynamics Controlled Study of NOV-001 in Healthy Volunteers and Patients With Enteric Hyperoxaluria
Phase 1-2a Safety, Tolerability, and Pharmacodynamics Controlled Study of NOV-001 in Healthy Volunteers and Patients With Enteric Hyperoxaluria
Enrollment Status: Terminated
Publish Date: May 17, 2023
Intervention Type: Drug, Biological, Combination product
Study Phase: Phase 1/Phase 2
Long-Term Prospective Registry to Evaluate Treatment Decisions and Clinical Outcomes in Patients With Favorable Intermediate-Risk Localized Prostate Cancer Following Cell Cycle Progression (CCP) Testing (Prolaris® Test)
Long-Term Prospective Registry to Evaluate Treatment Decisions and Clinical Outcomes in Patients With Favorable Intermediate-Risk Localized Prostate Cancer Following Cell Cycle Progression (CCP) Testing (Prolaris® Test)
Enrollment Status: Terminated
Publish Date: June 23, 2022
Intervention Type: Diagnostic test
An Evaluation of the Vesair® Bladder Control System for the Treatment of Stress Urinary Incontinence in Post-Menopausal Women
An Evaluation of the Vesair® Bladder Control System for the Treatment of Stress Urinary Incontinence in Post-Menopausal Women
Enrollment Status: Terminated
Publish Date: May 13, 2022
Intervention Type: Other, Device
Study Phase: Not Applicable
A Registry for Hereditary Cancer Risk Assessment and Genetic Testing Among Men With Prostate Cancer in the Community Urology Practice Setting
A Registry for Hereditary Cancer Risk Assessment and Genetic Testing Among Men With Prostate Cancer in the Community Urology Practice Setting
Enrollment Status: Completed
Publish Date: November 05, 2020
View 9 Less Clinical Trials

7 Total Publications

Prolonged Progression-Free Survival, Disease-Free Survival and Cystectomy Avoidance with IL-15 Receptor Lymphocyte-Stimulating Agent NAI plus BCG in BCG-Unresponsive Papillary-Only NMIBC.
Prolonged Progression-Free Survival, Disease-Free Survival and Cystectomy Avoidance with IL-15 Receptor Lymphocyte-Stimulating Agent NAI plus BCG in BCG-Unresponsive Papillary-Only NMIBC.
Journal: The Journal of urology
Published: September 16, 2025
View All 7 Publications
Similar Doctors
Daniel J. George
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Daniel J. George
Urology | Hematology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Daniel J. George
Urology | Hematology | Oncology

Duke Cancer Center

20 Duke Medicine Cir, 
Durham, NC 
 (18.4 miles away)
919-681-6900
Experience:
33+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

I specialize in the care of patients with urologic cancers – mainly prostate cancer, kidney cancer, bladder cancer and testicular cancer. A cancer diagnosis is one of the scariest things that can happen to someone. For many of our patients, they don’t necessarily feel different or look different, but they are scared to death. The most important thing you can get from Duke is real understanding of your particular case and what your options are. Knowledge is so reassuring and empowering for patients, especially those recently diagnosed with cancer. When you’re first diagnosed, you have to put your trust in a care team, and that’s hard to do if you don’t already know them. As the largest cancer center in North Carolina, Duke has great reputation and experience, which helps many patients chose Duke for their care. But we grow and develop our trust with patients because of who we are as people and how much expertise and care we bring to each case. Dr. George is rated as an Elite provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Prostate Cancer, Renal Cell Carcinoma (RCC), Familial Prostate Cancer, Nephrectomy, and Orchiectomy.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Mathew C. Raynor
Urology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Mathew C. Raynor
Urology

University Of North Carolina At Chapel Hill

101 Manning Dr, 
Chapel Hill, NC 
 (20.7 miles away)
984-974-1000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Mathew Raynor is an Urologist in Chapel Hill, North Carolina. Dr. Raynor is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Retroperitoneal Fibrosis, Renal Cell Carcinoma (RCC), Intussusception in Children, Nephrectomy, and Reconstructive Urology Surgery. Dr. Raynor is currently accepting new patients.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Thomas A. Longo
Urology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Thomas A. Longo
Urology

Associated Urologists Of North Carolina PA

3821 Ed Dr, 
Raleigh, NC 
 (0.1 miles away)
919-758-8677
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Thomas Longo is an Urologist in Raleigh, North Carolina. Dr. Longo is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Reconstructive Urology Surgery, and Nephrectomy. Dr. Longo is currently accepting new patients.

VIEW MORE WT1-RELATED WILMS TUMOR SYNDROMES DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Jalkut's expertise for a condition
ConditionClose
    • Distinguished
    • Familial Prostate Cancer
      Dr. Jalkut is
      Distinguished
      . Learn about Familial Prostate Cancer.
      See more Familial Prostate Cancer experts
    • Muscle Invasive Bladder Cancer
      Dr. Jalkut is
      Distinguished
      . Learn about Muscle Invasive Bladder Cancer.
      See more Muscle Invasive Bladder Cancer experts
    • Prostate Cancer
      Dr. Jalkut is
      Distinguished
      . Learn about Prostate Cancer.
      See more Prostate Cancer experts
    • Advanced
    • Acute Cystitis
      Dr. Jalkut is
      Advanced
      . Learn about Acute Cystitis.
      See more Acute Cystitis experts
    • Bilateral Hydronephrosis
      Dr. Jalkut is
      Advanced
      . Learn about Bilateral Hydronephrosis.
      See more Bilateral Hydronephrosis experts
    • Bladder Cancer
      Dr. Jalkut is
      Advanced
      . Learn about Bladder Cancer.
      See more Bladder Cancer experts
    • Boils
      Dr. Jalkut is
      Advanced
      . Learn about Boils.
      See more Boils experts
    • Carbuncle
      Dr. Jalkut is
      Advanced
      . Learn about Carbuncle.
      See more Carbuncle experts
    • Chromophobe Renal Cell Carcinoma
      Dr. Jalkut is
      Advanced
      . Learn about Chromophobe Renal Cell Carcinoma.
      See more Chromophobe Renal Cell Carcinoma experts
    View All 32 Advanced Conditions
    • Experienced
    • Asymptomatic Bacteriuria
      Dr. Jalkut is
      Experienced
      . Learn about Asymptomatic Bacteriuria.
      See more Asymptomatic Bacteriuria experts
    • Balanitis
      Dr. Jalkut is
      Experienced
      . Learn about Balanitis.
      See more Balanitis experts
    • Bladder Outlet Obstruction
      Dr. Jalkut is
      Experienced
      . Learn about Bladder Outlet Obstruction.
      See more Bladder Outlet Obstruction experts
    • Bladder Reconstruction
      Dr. Jalkut is
      Experienced
      . Learn about Bladder Reconstruction.
      See more Bladder Reconstruction experts
    • Bladder Stones
      Dr. Jalkut is
      Experienced
      . Learn about Bladder Stones.
      See more Bladder Stones experts
    • Choriocarcinoma
      Dr. Jalkut is
      Experienced
      . Learn about Choriocarcinoma.
      See more Choriocarcinoma experts
    View All 23 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2025 All Rights Reserved